Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence

• DOI: 10.21147/j.issn.1000-9604.2023.04.06
• Publication Date: 2023-09-07T04:32:15Z
• Authors: Jianguo Wang; ; Xiaonan Xiang; Zhixiong Shi; Hui Zhang; Quanbao Zhang; Zhikun Liu; Guangjie Zhao; Chuanxing Wu; Qiang Wei; Lin Zhong; Zhengxin Wang; Guoyue Lv; Shusen Zheng; Xiao Xu
• Keywords: Clinical endpoint; Transcatheter arterial chemoembolization; Adjuvant Therapy

Hepatocellular carcinoma (HCC) has a high rate of postoperative recurrence and lacks an effective treatment to prevent recurrence. This study aims investigate the efficacy safety anlotinib in adjuvant therapy for HCC patients with high-risk factors.For this multicenter, retrospective study, we recruited 63 who received either (n=27) or transcatheter arterial chemoembolization (TACE) (n=36) from six research centers China between March 2019 October 2020. The primary endpoint was disease-free survival (DFS) secondary endpoints were overall (OS) safety.In median follow-up time 25.9 26.8 months TACE groups, respectively. There no significant difference DFS [26.8 months, 95% confidence interval (95% CI): 6.8-NE] groups (20.6 CI: 8.4-NE). 12-month OS rates 96.3% 97.2%, In group, 19 27 (70.4%) experienced treatment-emergent adverse events, most common events (≥10%) being hypertension (22.2%) decreased platelet count (22.2%).The results indicate that anlotinib, as new, orally administered tyrosine kinase inhibitor, same TACE, side effects can be well controlled.